THE WOODLANDS, Texas, September 1 /PRNewswire/ -- Berlin Heart Inc. reported today that it has completed enrollment in Cohort 1 of the Berlin Heart EXCOR(R) Pediatric IDE Study after having received unconditional approval of the study from the FDA in November 2008.
The Principal Investigator, Dr. Charles Fraser, Chief of Congenital Heart
Surgery at Texas Children's Hospital and Professor of Surgery and Pediatrics
The last two patients implanted in this Cohort were implanted at Texas Children's Hospital in Houston, Texas by Dr. David Morales and at Children's Hospital of Wisconsin in Milwaukee, Wisconsin by Dr. James Tweddell.
Dr. Johannes Mueller, CEO of Berlin Heart commented, "Berlin Heart is proud that the EXCOR device is the first ventricular assist device to be involved in a prospective clinical trial involving the pediatric population. We are very pleased with the early clinical results of the study and are excited as this milestone brings us closer to our goal of making this device more readily available for sick children in the US."
Bob Kroslowitz, Vice President of Clinical Affairs for Berlin Heart said, "This is an outstanding achievement for the whole team. We especially thank our study sites, our investigators and most importantly, the families of the children that have been enrolled in the study. We look forward to compiling the results and submitting an application to the FDA for approval for this important group of patients while we continue to enroll additional pediatric patients into Cohort 2 of the study."
Implants of the EXCOR Pediatric device for Coh
|SOURCE Berlin Heart GmbH|
Copyright©2009 PR Newswire.
All rights reserved